GASTROINTESTINAL CANCERS 2020
Current and Emerging Strategies in Multidisciplinary Care
Translating Evidence into Best Practice

INTERCONTINENTAL SAN DIEGO
SAN DIEGO, CALIFORNIA
MARCH 5–7, 2020

$75 DISCOUNT IF YOU REGISTER ON OR BEFORE JAN 30, 2020

CE.MAYO.EDU/GICANCER2020
COURSE HIGHLIGHTS

• Case-based didactic presentations and panel discussions from Mayo Clinic and world renowned experts in the treatment of gastrointestinal cancers including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal, colorectal and gallbladder

• State-of-the-art updates providing practitioners with the best and most current evidence to integrate into their day-to-day routine care of patients with GI cancers

• Practical and clinically relevant perspective on providing optimal multidisciplinary care for complex clinical management decisions in gastrointestinal oncology including but not limited to locoregional modalities, the role of minimally invasive procedures and state-of-the-art radiation modalities

• Special education session for advanced practice providers and pharmacists – Optimizing Management Strategies for Common Immunotherapy and TKI-Related Toxicities in Patients Diagnosed with GI Cancer

• Continuing education credit offered for physicians, nurses and pharmacists

TARGET AUDIENCE

This course is designed for medical oncologists, radiation oncologists, surgical oncologists, GI surgeons, gastroenterologists and hepatologists involved in cancer care, interventional radiologists, nurse practitioners, physician assistants, nurses and pharmacists. Other healthcare providers interested in the care of patients diagnosed with GI malignancies may benefit from this program.

LEARNING OBJECTIVES

Upon conclusion of this program, participants should be able to:

• Interpret the most up-to-date and practice-relevant data presented at various cancer-related meetings in 2019 and 2020

• Integrate evidence-based interdisciplinary treatment strategies into clinical practice in various fields of medical oncology

• Determine the usefulness of genomic and immune-based treatment approaches in oncology

• Review the current and future role of immunotherapy strategies in various GI malignancies

• Select the appropriate treatment strategy for patients with early stage cancers of GE junction, rectum, pancreas, and liver

• Identify ideal patients with neuroendocrine tumors that would be candidates for radionuclide therapy

• Describe the molecular biology and genetics of colorectal cancers

• State the appropriate regimens for sequencing therapies across multiple GI malignancies

COURSE DIRECTORS

Steven R. Alberts, M.D.  Tanios S. Bekaii-Saab, M.D.
REGISTRATION

<table>
<thead>
<tr>
<th>Registration Fee</th>
<th>On or Before Jan 30</th>
<th>After Jan 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians/Scientists</td>
<td>$650</td>
<td>$725</td>
</tr>
<tr>
<td>Residents, Fellows, Nurse Practitioners, Physician Assistants, Pharmacists, Allied Health</td>
<td>$550</td>
<td>$625</td>
</tr>
</tbody>
</table>

Visit ce.mayo.edu/cancellation for more information.

ACCOMMODATIONS

InterContinental San Diego
901 Bayfront Court | San Diego, California 92101
Telephone: (800) 439-4745 | Website: https://www.intercontinentalsandiego.com
Reservations: https://www.intercontinentalsandiego.com/gi-cancer-course

A block of rooms at a special group rate of $309 (USD), plus applicable city and state sales tax, per night, is available at the InterContinental San Diego for course participants and guests. Rates are based on single, double, trip and quad occupancy. Children under the age of 18 years will stay complimentary in same room with parent. Group rates apply three days prior to and three days after course dates, based upon availability.

Self-parking is discounted to $25. Bell staff porterage and housekeeping gratuities are optional and to be paid at the individual guest’s discretion. The daily amenity fee of $25 plus tax is waived upon check-in and includes high-speed internet in the guest room, bottled water, local and domestic calls, business lounge use and health and wellness center access. Check-in time is 3:00 p.m.; check-out time is 11:00 a.m.

Make your reservation before the room block fills or by February 12, 2020, via website or telephone, and reference “Mayo Clinic GI Cancer”.

The standard hotel reservation cancellation policy will apply to individual reservations with no fee to the individual if it is prior to 72 hours to arrival. A cancellation or arrival date change less than seventy-two (72) hours prior to arrival will result in a charge equal to one night’s room and tax. In the event a guest holding a reservation within the group block checks out prior to the guest’s reservation check-out date, the hotel will add an early check-out fee of one (1) night’s room and tax, to the guest’s account.

CREDIT

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA: Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE: Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 14.50 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ANCC: Participants can earn up to 14.50 ANCC nursing contact hours commensurate with the extent of their participation in the activity. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AOA: The American Osteopathic Association designates this program for a maximum of 14.50 AOA Category 2-A credits.

Other Healthcare Professionals: A certificate of attendance will be provided to other healthcare professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

ABIM Maintenance of Certification:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared with ABIM through PARS.
Thursday, March 5, 2020

• Opening Remarks and Keynote Lecture: Next Generation Sequencing (and Beyond) for Patients with Gastrointestinal Cancer: Making the Case for Universal Testing
• Welcome Reception and Poster Walk

Friday, March 6, 2020

• Interactive Case Presentation - Oligometastatic Disease in Pancreas Cancer: Is There a Role for Locoregional Therapy?
• PARP Inhibitors in Select Patients with Metastatic Pancreas Cancer: Are We There Yet?
• Emerging (non-HRD) Targets in Metastatic Pancreas Cancer: Lessons Learned
• Interactive Case Presentation – Challenging Cases in the Treatment of High-Risk Early Stage Colon Cancer
• Clinical Utility of Circulating Tumor DNA in Patients with mCRC
• Optimizing Therapeutic Strategies in Patients with BRAF V600E Mutated mCRC
• Therapeutic and Prognostic Implications of HER2 Amplified mCRC
• Interactive Case Presentation – Individualized Approaches in Early Stage Rectal Cancer
• Reirradiation and Proton Therapy in Patients with Locoregional Recurrence of Anorectal Cancer
• Optimizing the Role of Systemic Therapy in Patients with Oligometastatic mCRC
• Next Frontiers in Immunotherapy and MSS mCRC
• Interactive Case Presentation – Radionucleotide Therapy in Neuroendocrine Cancer
• Special Education Session for Advanced Practice Providers and Pharmacists – Optimizing Management Strategies for Common Immunotherapy and TKI-Related Toxicities in Patients Diagnosed with GI Cancer
  ◦ Challenges in Identifying and Managing Immune-Related Toxicities
  ◦ Challenges in Managing TKI-Related Toxicities

Saturday, March 7, 2020

• Interactive Case Presentation – Early Stage HCC and Transplant: When Is A “Bridge” Needed?
• Immunotherapy in HCC: It is Complicated!
• Advanced Biliary Tract Cancer: Targets Galore!
• Interactive Case Presentation – Perioperative Chemotherapy With or Without Radiation in Patients with Early Stage Gastro-Esophageal Cancers
• The Role of Advanced Endoscopy in the Diagnosis and Treatment of Barrett’s Esophagus
• Optimizing Surgical Outcomes in Patients with Early Stage GE Cancer
• Metastatic Refractory GE Cancer: Where Should Immunotherapy Fit into the Treatment Algorithm?
• Interactive Genomic Tumor Board: Management of Complex Rare GI Cancer Cases
  ◦ Patient Case #1: A 56-year-old female patient with MSI-H mCRC and a BRAF V600E mutation
  ◦ Patient Case #2: A 52-year-old male with MSI-H mCRC and an NTRK fusion
  ◦ Patient Case #3: A 48-year-old female with MSI-H metastatic pancreas cancer and a BRCA2 mutation
Course Directors
Steven R. Alberts, M.D.         Tanios S. Bekaii-Saab, M.D.

Guest Faculty

Hani M. Babiker, M.D.
University of Arizona Cancer Center
Tucson, Arizona

Daniel Catenacci, M.D.
The University of Chicago
Medical Center & Biological Sciences
Chicago, Illinois

Kristen Ciombor, M.D., M.S.C.I.
Vanderbilt University Medical Center
Nashville, Tennessee

Michel Duceux, M.D., Ph.D.
Institut of Gustave Roussy
Paris, France

Anthony B. El-Khoueiry, M.D.
Southern California Clinical and Translational Science Institute
University of Southern California
Los Angeles, California

Bassel F. El-Rayes, M.D.
Emory University
Atlanta, Georgia

Scott Kopetz, M.D., Ph.D., F.A.C.P.
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Christopher Lieu, M.D.
University of Colorado
Anschutz Medical Campus
Aurora, Colorado

John L. Marshall, M.D.
Medstar Georgetown University Hospital
Washington, D.C.

Eiji Oki, M.D., Ph.D.
Kyushu University Hospital
Fukuoka, Japan

Michael J. Pishvaian, M.D., Ph.D.
The University of Texas
MD Anderson Cancer Center
Houston, Texas

John H. Strickler, M.D.
Duke University School of Medicine
Duke Cancer Center
Durham, North Carolina

Hiroya Taniguchi, M.D.
National Cancer Center Hospital East
Chiba, Japan

Christina Wu, M.D.
Emory University School of Medicine
Atlanta, Georgia

Takayuki Yoshino, M.D.
National Cancer Center Hospital East
Chiba, Japan

Mayo Clinic Faculty

Daniel H. Ahn, D.O.
Jonathan B. Ashman, M.D., Ph.D.
Staci E. Beamer, M.D.
Mitesh J. Borad, M.D.
Travis E. Grotz, M.D.
Thorvardur R. Halfdanarson, M.D.
Christopher (Chris) L. Hallemeyer, M.D.
Timothy J. Hobday, M.D.
Joleen M. Hubbard, M.D.
Zhaohui Jin, M.D.
Sunit Krishnan, M.B.B.S., M.D.
Wen Wee Ma, M.B.B.S.
Kellie L. Mathis, M.D.
Amit K. Mathur, M.D.
Andrea L. McNatty, Pharm.D., R.Ph.
Robert R. McWilliams, M.D.
Amit Merchea, M.D.
Nitin Mishra, M.B.B.S., M.P.H.

Jessica L. Mitchell, A.P.R.N., C.N.P.
Kabir Mody, M.D.
Tushar C. Patel, M.B., Ch.B.
Sarine Ravanbakhsh, M.D.
William G. Rule, M.D.
K. Robert Shen, M.D.
Frank A. Sinicropo, M.D.
Terence T. Sio, M.D., M.S.
Mohamad (Bassam) B. Sonbol, M.D.
Jason S. Starr, D.O.
Chee-Chee H. Stucky, M.D.
Beau Toskich, M.D.
Michael B. Wallace, M.D.
Herbert C. Wolfsen, M.D.
Harry H. Yoon, M.D.
Visit our course website for additional information.

CE.MAYO.EDU/GICANCER2020